Trials / Unknown
UnknownNCT06239506
Novel Brominated and Organophosphate Flame Retardants and Type 2 Diabetes
Exposure to Novel Brominated and Organophosphate Flame Retardants and Associations With Type 2 Diabetes
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 340 (estimated)
- Sponsor
- Xiaoling Guan · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
As alternative flame retardants (FRs), novel brominated flame retardants (NBFRs) and organophosphate flame retardants (OPFRs) are ubiquitous in environment and may cause endocrine disruption effects. The associations between traditional endocrine-disrupting chemicals (EDCs) and type 2 diabetes have been extensively reported in epidemiological studies. To date, however, human-based evidence on the effects of NBFRs and OPFRs is lacking. The investigators conducted a case-control study of 344 participants aged 25-80 years from Shandong Province, East China, to assess potential associations between serum NBFR and OPFR concentrations and etiology of type 2 diabetes for the first time.
Detailed description
In this study, the investigators conducted a case-control study in Shandong Province, East China, to evaluate the associations between serum NBFR and OPFR and risk of type 2 diabetes. The aims of the present study were to (1) evaluate the associations between alternative FRs in human serum and the risk of type 2 diabetes, (2) assess the relationships between alternative FR concentrations and fasting plasma glucose (FPG), (3) investigate the correlations between alternative FRs and concentrations of lipid fractions, including TG, TC, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), and (4) clarify the joint effects of NBFR and OPFR mixtures on the risk of type 2 diabetes
Conditions
- Type 2 Diabetes
- Novel Brominated Flame Retardants
- Organophosphate Flame Retardants
- Fasting Plasma Glucose
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | no intervention | no intervention |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
- First posted
- 2024-02-02
- Last updated
- 2024-02-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06239506. Inclusion in this directory is not an endorsement.